Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study
- PMID: 23842215
- DOI: 10.1097/MCG.0b013e31829ae376
Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study
Abstract
Goals: In this pilot study, we compared midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction (PICD).
Background: PICD with pronounced arterial vasodilatation in cirrhotics with tense ascites can be prevented by the infusion of albumin, which is an expensive treatment modality. Various vasoconstrictors have also been used to prevent PICD, but there are few studies about the usage of midodrine.
Study: Fifty patients with cirrhosis and tense refractory ascites were randomly assigned to be treated with either midodrine (n=25) (12.5 mg 3 times/d; over 3 d) or albumin (n=25) (8 g/L of removed ascites) after a large-volume paracentesis. Effective arterial blood volume was assessed indirectly by measuring serum creatinine, serum sodium, plasma renin activity, and aldosterone concentration before and 6 days after paracentesis.
Results: Midodrine therapy was cheaper compared with albumin therapy, but serum creatinine, serum sodium, plasma renin activity, and plasma aldosterone concentration values after treatment [0.99±0.19 to 3.02±2.58 mg/dL (P=0.001), 132.36±3.2 to 130.2±4.1 mEq/L (P<0.001), 3.03±0.33 to 4.2±0.76 ng/mL/h (P<0.001), and 166.72±64.26 to 298.64±130 pg/mL (P<0.001), respectively] significantly differed in the midodrine group from that in the albumin group [1.10±0.22 to 1.11±0.161 mg/dL (P=0.885), 132.2±3.524 to 131.88±3.09 mEq/L (P=0.246), 4±0.91 to 4.11±0.74 ng/mL/h (P=0.440), and 204.88±115.9 to 177.08±100.5 pg/mL (P<0.001), respectively]. Seven patients, among whom 6 were hepatocellular carcinoma (HCC) positive, in the midodrine group of our study died as a consequence of liver failure complicated by acute renal failure, followed by hepatic encephalopathy. Whereas in the albumin group, even among the 7 patients with HCC, no patient died or developed hepatorenal syndrome or developed hepatic encephalopathy.
Conclusions: This pilot study suggests that midodrine is not as effective as intravenous albumin in preventing circulatory dysfunction after large-volume paracentesis in patients with cirrhosis and tense ascites, especially with HCC-positive patients.
Comment in
-
Midodrine for paracentesis-induced circulatory dysfunction.J Clin Gastroenterol. 2014 Mar;48(3):300. doi: 10.1097/MCG.0b013e3182a8bfaf. J Clin Gastroenterol. 2014. PMID: 24100756 No abstract available.
-
In response.J Clin Gastroenterol. 2014 Mar;48(3):300-1. doi: 10.1097/MCG.0000000000000003. J Clin Gastroenterol. 2014. PMID: 24202000 No abstract available.
Similar articles
-
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.Liver Int. 2008 Aug;28(7):1019-25. doi: 10.1111/j.1478-3231.2008.01734.x. Epub 2008 Apr 11. Liver Int. 2008. PMID: 18410283 Clinical Trial.
-
Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.Am J Gastroenterol. 2008 Jun;103(6):1399-405. doi: 10.1111/j.1572-0241.2008.01787.x. Am J Gastroenterol. 2008. PMID: 18547224 Clinical Trial.
-
Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7. doi: 10.1111/j.1440-1746.2006.04182.x. J Gastroenterol Hepatol. 2006. PMID: 16460491 Clinical Trial.
-
Colloids Versus Albumin in Large Volume Paracentesis to Prevent Circulatory Dysfunction: Evidence-based Case Report.Acta Med Indones. 2016 Apr;48(2):148-55. Acta Med Indones. 2016. PMID: 27550886 Review.
-
Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.Ann Pharmacother. 2009 Apr;43(4):692-9. doi: 10.1345/aph.1L373. Epub 2009 Mar 18. Ann Pharmacother. 2009. PMID: 19299324 Review.
Cited by
-
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD013123. doi: 10.1002/14651858.CD013123.pub2. Cochrane Database Syst Rev. 2020. PMID: 31978257 Free PMC article.
-
Hepatorenal syndrome: outcome of response to therapy and predictors of survival.Gastroenterol Res Pract. 2015;2015:457613. doi: 10.1155/2015/457613. Epub 2015 Apr 23. Gastroenterol Res Pract. 2015. PMID: 25983746 Free PMC article.
-
Midodrine versus Albumin to Prevent Paracentesis Induced Circulatory Dysfunction in Acute on Chronic Liver Failure Patients in the Outpatient Clinic-a Randomized Controlled Trial.J Clin Exp Hepatol. 2023 Jul-Aug;13(4):576-585. doi: 10.1016/j.jceh.2023.01.009. Epub 2023 Jan 28. J Clin Exp Hepatol. 2023. PMID: 37440947 Free PMC article.
-
Midodrine in Liver Cirrhosis With Ascites: A Systematic Review and Meta-Analysis.Cureus. 2022 Jul 30;14(7):e27483. doi: 10.7759/cureus.27483. eCollection 2022 Jul. Cureus. 2022. PMID: 36060403 Free PMC article. Review.
-
Albumin administration in patients with cirrhosis: Current role and novel perspectives.World J Gastroenterol. 2022 Sep 7;28(33):4773-4786. doi: 10.3748/wjg.v28.i33.4773. World J Gastroenterol. 2022. PMID: 36156923 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources